Health & Biotech Why all eyes are on Neuren Pharmaceuticals as it awaits crucial FDA approval in March February 24, 2023 The US FDA is expected to decide on March 12 as to whether it approves ASX-listed biotech Neuren's trofinetide for… Weed Week: Musk gives the go-ahead for cannabis advertising on Twitter in the US February 23, 2023 Twitter has become the first social media platform to give cannabis advertising the all-clear - in US states where weed… ASX Health Stocks: Partnership deals send Avecho shares flying this morning February 22, 2023 A couple of partnership deals announced by Anteotech and Avecho saw those two biotechs gain double digits this morning. Health Kick Podcast: Aussie Bio Tech Medlab is confident in highly anticipated Phase III trial February 22, 2023 Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment… Dimerix CEO says phase 3 trials means much higher chance of taking its kidney drug to market February 21, 2023 Special Report: Dimerix (ASX:DXB) is one of very few Australian biotech companies to progress to a drug candidate to phase… Race welcomes new CEO as it looks beyond the clinic for potential partners and investors February 21, 2023 Special Report: It’s an exciting time for Race Oncology investors as the company appoints a new CEO and presses forward… PharmAust doses first MND patient in second cohort with larger MPL dose February 20, 2023 Special Report: PharmAust has dosed the first patient of the second cohort in its Phase 1/2 Motor Neurone Disease (MND)… ASX Health Stocks: HeraMED is traveling smoothly in the US; Recce names Adelaide firm to run Phase1/2 trial February 20, 2023 Maternity care medtech company, HeraMED (ASX:HMD), says its initial first phase commercial rollout in the US is progressing well. EZZ now has green light to sell Kourtney Kardashian’s favourite anti-ageing supplement in China February 20, 2023 Special Report: China’s approval of NMN supplements as food additives is expected to launch EZZ further into the Chinese supplements… Dr Boreham’s Crucible: With new blood at the top, can CSL continue its reign? February 18, 2023 Rather like last year’s changing of the throne at Buckingham Palace, regime change is a rarity at CSL (ASX:CSL), so… Next» « Previous